Sutro Biopharma, Inc. (NASDAQ:STRO) Receives $49.11 Average Target Price from Analysts

Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) have been given an average rating of “Buy” by the thirteen analysts that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, eight have assigned a buy recommendation and three have assigned a strong buy recommendation to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $49.1111.

A number of equities analysts have recently issued reports on STRO shares. Citizens Jmp increased their price objective on shares of Sutro Biopharma from $35.00 to $41.00 and gave the stock a “market outperform” rating in a research report on Thursday, April 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Sutro Biopharma in a research report on Friday, May 8th. Barclays initiated coverage on shares of Sutro Biopharma in a research report on Thursday, May 28th. They issued an “overweight” rating and a $56.00 price target on the stock. Truist Financial raised shares of Sutro Biopharma to a “strong-buy” rating in a research report on Monday, May 4th. Finally, Mizuho set a $50.00 price target on shares of Sutro Biopharma and gave the company an “outperform” rating in a research report on Thursday, April 30th.

Hedge Funds Weigh In On Sutro Biopharma

Large investors have recently added to or reduced their stakes in the business. Bridgeway Capital Management LLC lifted its position in Sutro Biopharma by 232.6% in the 3rd quarter. Bridgeway Capital Management LLC now owns 42,900 shares of the company’s stock valued at $37,000 after acquiring an additional 30,000 shares in the last quarter. Invesco Ltd. lifted its position in Sutro Biopharma by 137.8% in the 1st quarter. Invesco Ltd. now owns 92,139 shares of the company’s stock valued at $60,000 after acquiring an additional 53,390 shares in the last quarter. Cerity Partners LLC lifted its position in Sutro Biopharma by 169.9% in the 2nd quarter. Cerity Partners LLC now owns 105,437 shares of the company’s stock valued at $75,000 after acquiring an additional 66,372 shares in the last quarter. Qube Research & Technologies Ltd bought a new position in Sutro Biopharma in the 2nd quarter valued at about $82,000. Finally, State of Tennessee Department of Treasury bought a new position in Sutro Biopharma in the 4th quarter valued at about $86,000. Institutional investors own 96.99% of the company’s stock.

Sutro Biopharma Price Performance

STRO stock opened at $27.18 on Monday. The stock has a market capitalization of $450.37 million, a PE ratio of -2.46 and a beta of 1.54. The company’s 50-day moving average is $30.66 and its 200-day moving average is $20.08. Sutro Biopharma has a 1 year low of $6.74 and a 1 year high of $43.85.

Sutro Biopharma (NASDAQ:STRO) last released its quarterly earnings data on Thursday, May 14th. The company reported ($2.94) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.74) by ($0.20). The firm had revenue of $14.52 million for the quarter, compared to the consensus estimate of $8.89 million. On average, analysts anticipate that Sutro Biopharma will post -8.81 earnings per share for the current fiscal year.

About Sutro Biopharma

Sutro Biopharma, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems.

Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development.